RenovoRx Aims 36 Active Sites by 2026, Poised for $3–4M Q1 Revenue
RenovoRx ended 2025 with nine active sites ordering catheters and has 12 centers treating patients, with 21 more in approval pipelines, targeting 36 active centers by end 2026. Management projects Q1 2026 revenue of $3 million to $4 million driven by new center additions and recurring treatments.
1. Trial Center Transition and Activation
RenovoRx has 12 centers actively treating patients and nine centers currently ordering catheters. Transition from TIGeR-PaC trial sites to commercial customers is expedited by existing physician training, pricing agreements, VAC approvals and referral patterns, although internal approvals and patient identification remain scaling challenges.
2. Pipeline Expansion Targets
The company plans to triple its commercial footprint from nine active ordering sites at year-end 2025 to 36 active centers by end 2026. An additional 21 centers are in the VAC approval process or preparing for activation, underpinning the growth runway.
3. Revenue Guidance and Sales Team Plan
Management projects Q1 2026 revenue of $3 million to $4 million driven by new center activations and recurring treatments. The current sales team of three will be supplemented by two hires to support regional coverage and accelerate site activations.